Ovarian Cancer | Specialty

Chemotherapy in Early-Stage Ovarian Cancer

July 27th 2018

Surgery in Early-Stage Ovarian Cancer

July 27th 2018

Dr. Konstantinopoulos on Rationale for TOPACIO Trial in Ovarian Cancer

July 25th 2018

Panagiotis A. Konstantinopoulos, MD, PhD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the rationale behind the TOPACIO trial for the treatment of patients with recurrent ovarian cancer.

Dr. Matulonis Discusses Rationale of QUADRA Trial

July 24th 2018

Ursula A. Matulonis, MD, chief, Division of Gynecological Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the rationale behind the QUADRA trial for patients with relapsed ovarian cancer.

Dr. Markman on Latest Advances in Treatment of Gynecological Malignancies

July 18th 2018

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, discusses the latest advances in treatment for gynecological malignancies and other tumor types.

Dr. Hardesty on Second-Line Maintenance Therapy for Ovarian Cancer

July 17th 2018

Melissa Hardesty, MD, gynecologic oncologist, Alaska Women’s Cancer Center, discusses second-line maintenance therapy after frontline chemotherapy for patients with ovarian cancer.

Dr. Konecny on Resistance to PARP Inhibitors in Ovarian Cancer

July 17th 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses resistance to PARP inhibitors in ovarian cancer.

Dr. Pietras Discusses Pain Management in Ovarian Cancer

July 13th 2018

Christopher J. Pietras, MD, director, Palliative Care, assistant clinical professor, University of California, Los Angeles (UCLA) School of Medicine, discusses pain management in patients with ovarian cancer.

Expert Stresses Importance of Genetic Testing in Ovarian Cancer

July 12th 2018

Deborah Krakow, MD, discusses the value of a patient’s family history and its implications on genetic counseling.

Pietras Presents Pillars of Palliative Care in Ovarian Cancer

July 12th 2018

Christopher J. Pietras, MD, discusses the elements of palliative care for patients with ovarian cancer.

Antibody-Directed Therapeutic Research Ongoing in Ovarian Cancer

July 12th 2018

Sanaz Memarzadeh, MD, PhD, details the early developments of antibody-directed therapies and restoring p53 function in the treatment of patients with ovarian cancer.

Expert Tracks the Activity of PARP Inhibitors in Ovarian Cancer

July 11th 2018

Gottfried E. Konecny, MD, discusses developments in the understanding of response to PARP inhibition in ovarian cancer.

Efforts Continue to Increase Immunotherapy Impact in Gynecologic Cancers

July 10th 2018

John A. Glaspy, MD, discusses challenges and progress with immunotherapy in gynecologic cancers.

Slamon Specifies Next Steps in Ovarian Cancer Treatment

July 3rd 2018

Dennis J. Slamon, MD, PhD, discusses new opportunities for treatment advances in ovarian cancer.

Addressing PARP Inhibitor Resistance in Ovarian Cancer

July 2nd 2018

Kelly McCann, MD, PhD, discusses the process of DNA damage and repair, resistance to PARP inhibitors, and rational combination strategies to overcome resistance.

Dr. Rao on Testing for Somatic and Germline Mutations

June 29th 2018

Jianyu Rao, MD, professor and chief of Cytopathology, University of California, Los Angeles, discusses testing for somatic and germline mutations in patients with ovarian cancer.

Olaparib Improves PFS as Frontline Maintenance in Ovarian Cancer

June 27th 2018

Olaparib tablets reduced the risk of disease progression or death compared with placebo as frontline maintenance therapy for women with BRCA-positive advanced ovarian cancer, according to findings from the randomized phase III SOLO-1 trial.

Ovarian Cancer Incidence, Mortality Decline But Access to Care Is Not Equal

June 26th 2018

Ovarian cancer incidence and mortality have declined significantly over the past few decades, but eliminating racial disparities in treatment and improving prevention and early detection could help save even more women.

Dr. Sasine on CAR T-Cell Therapy in Ovarian Cancer

June 25th 2018

Joshua P. Sasine, MD, medical director, Chimeric Antigen Receptor T-Cell Program, David Geffen School of Medicine, University of California, Los Angeles, discusses chimeric antigen receptor (CAR) T- cell therapy in ovarian cancer.

FDA Approves Bevacizumab as Frontline Ovarian Cancer Treatment After Surgery

June 13th 2018

The FDA has approved bevacizumab for use in combination with carboplatin and paclitaxel, followed by bevacizumab monotherapy, for the treatment of women with advanced ovarian cancer following initial surgical resection.